In this episode we discuss obinutuzumab for lupus nephritis and anti-CD19 CAR T Cell therapy for autoimmune rheumatic disease. Links to the B-Cell Breakaway Scouting Reports: Obinutuzumab in lupus nephritis, by the University of Michigan Adult Rheumatology Fellowship ProgramCD-19 CAR T-cell therapy, by the Vanderbilt University Adult Rheumatology Fellowship ProgramSTRAP trial, by the Emerging EULAR Network (EMEUNET) Links to theMednet.org Q&As about this region: In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?What are the potential barriers to the widespread use of obinutuzumab in proliferative lupus nephritis?How do you envision incorporating CAR-T therapy into your clinical practice?Does synovial biopsy provide diagnostic value in undifferentiated inflammatory arthritis? To learn more about RheumMadness:https://sites.duke.edu/rheummadness/Subscribe to our newsletter:https://lists.duke.edu/sympa/subscribe/rheummadnessFind us on social media:Bluesky: @rheummadness.bsky.socialInstagram: https://www.instagram.com/rheummadness/X: Follow #RheumMadnessIntro/outro music: Cheery Monday by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/3495-cheery-mondayLicense: http://creativecommons.org/licenses/by/4.0/ Rss Apple Podcaster →
